Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VPS9D1 antisense RNA 1 (VPS9D1-AS1)
- Target
- VPS9D1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other (Antisense RNA)
01
Overview
VPS9D1 antisense RNA 1 (VPS9D1-AS1), also known as MYU, FAISL, or c-Myc-upregulated lncRNA, is a long non-coding RNA located antisense to the VPS9D1 gene on chromosome 16. It acts as an oncogene in multiple cancers, promoting cell proliferation, migration, invasion, and tumor growth. VPS9D1-AS1 functions mainly by regulating ribosome biogenesis and the cell cycle, acting as a scaffold for protein translation (including TGF-β and its signaling mediators). In colorectal cancer, it amplifies TGF-β and interferon-stimulated gene (ISG) signaling, driving immune evasion by decreasing T lymphocyte infiltration and facilitating resistance to cytotoxic T cell killing. In lung adenocarcinoma, VPS9D1-AS1 governs malignant progression via the miRNA-30a-5p/KIF11 axis, functioning as a competing endogenous RNA (ceRNA). Preclinical studies show that targeting VPS9D1-AS1 using antisense oligonucleotides can suppress tumor growth, supporting its role as a therapeutic target.
- Other names
- MYUFAISLFAK-interacting lncRNAc-Myc-upregulated lncRNA
02
Mechanism of action
Drugs (antisense oligonucleotides) inhibit VPS9D1-AS1 to suppress its oncogenic function and tumor growth
03
Biological functions
Cell proliferationCell cycle regulationRibosome biogenesisRNA modificationTranslation regulationImmune evasion (via TGF-β/ISG signaling axis)Signal transduction regulation (Wnt/β-catenin pathway, TGF-β pathway)
04
Disease associations
Cancer (colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, lung adenocarcinoma)Tumor progressionTumor immune evasion
05
Safety considerations
No specific safety concerns or challenges are reported in the available literature, but general challenges for lncRNA-targeted therapeutics include off-target effects and delivery efficiency
06
Interacting drugs
Antisense oligonucleotides targeting VPS9D1-AS1 (preclinical studies)
07
Biomarkers
VPS9D1-AS1 expressionKi-67 (proliferation index, affected by VPS9D1-AS1)β-catenin and c-Myc expression (correlated with VPS9D1-AS1 levels in tumors)
Beyond the preview
Go deeper on VPS9D1 antisense RNA 1 (VPS9D1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VPS9D1 antisense RNA 1 (VPS9D1-AS1).